FDA
-
-
-
-
-
-
-
Needham Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
-
-
-
-
-
-
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
-
-
-
-
-
-
-
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
-
-
-
-
-
-
-
Ionis announces board changes with two retirements, one addition
-
-
-
-
-
-
-
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
-
-
-
-
-
-
-
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
-
-
-
-
-
-
-
Biogen (BIIB): High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
-
325,888 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

